Balance Sheet (Annual)

UVE / Universal Insurance Holdings, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Assets
  Available For Sale Securities Debt Securities - - 289,418 353,949 416,083 584,361 639,334
  Short Term Investments - - - 49,990 25,021 5,002 10,000
  Available For Sale Securities Equity Securities - - 65,022 19,642 42,214 50,803 62,215
  Real Estate Investment Property Net - - - - 6,117 11,435 18,474
  Investments - - - - - - 730,023
  Cash And Cash Equivalents At Carrying Value 229,685 347,392 117,275 115,397 197,014 105,730 213,486
  Restricted Cash And Cash Equivalents 78,312 33,009 2,600 2,635 2,635 2,635 2,635
  Prepaid Reinsurance Premiums 243,095 239,921 241,214 190,505 114,673 124,385 132,806
  Reinsurance Recoverables 85,706 89,191 107,847 55,187 22,853 106 182,405
  Reinsurance Receivable Net - - - - - 186 -
  Premiums Receivable At Carrying Value 45,828 50,125 46,461 50,987 50,980 53,833 56,500
  Property Plant And Equipment Net 7,116 8,968 9,289 17,254 27,065 32,162 32,866
  Deferred Policy Acquisition Costs 12,996 17,282 - 25,660 60,019 64,912 73,059
  Income Tax Receivable - 2,594 8,152 5,675 5,420 3,262 9,472
  Deferred Tax Assets Liabilities Net 22,991 19,178 12,051 11,850 13,912 10,674 9,286
  Other Assets 1,477 1,578 2,072 2,812 4,563 4,883 12,461
  Assets 894,026 925,735 920,090 911,774 993,548 1,060,007 1,454,999
Liabilities And Stockholders Equity
  Liabilities
    Liability For Claims And Claims Adjustment Expense - - - 134,353 98,840 58,494 248,425
    Unearned Premiums 359,842 388,071 383,488 395,748 442,366 475,756 532,444
    Deposit Contracts Liabilities 19,390 15,022 22,959 17,919 24,813 17,796 26,216
    Accounts Payable Current And Noncurrent 4,314 4,368 3,441 4,121 378 3,187 2,866
    Book Overdraft - - 14,947 5,924 - - 36,715
    Reinsurance Payable 87,497 85,259 86,232 66,066 73,585 80,891 110,381
    Dividends Payable Current And Noncurrent - - - - - - -
    Other Accrued Liabilities Current And Noncurrent 24,780 28,071 34,386 36,318 36,424 37,665 45,096
    Long Term Debt 21,691 20,221 37,240 30,610 24,050 15,028 12,868
    Liabilities 744,021 762,221 744,481 692,858 700,456 688,817 1,015,011
  Commitments And Contingencies - - - - - - -
  Stockholders Equity
    Preferred Stock Value 1 1 - - - - -
    Common Stock Value 411 419 436 448 455 453 458
    Treasury Stock Value 3,101 3,101 35,467 62,153 80,802 86,982 105,123
    Additional Paid In Capital 36,536 38,684 42,282 40,987 70,789 82,263 86,186
    Accumulated Other Comprehensive Income Loss Net Of Tax - 0 -376 -1,835 -4,006 -6,408 -6,281
    Retained Earnings Accumulated Deficit 116,158 127,511 168,734 222,469 306,656 381,864 464,748
    Stockholders Equity 150,005 163,514 175,609 199,916 293,092 371,190 439,988
  Liabilities And Stockholders Equity 894,026 925,735 920,090 911,774 993,548 1,060,007 1,454,999

Peers - Fire, Marine, and Casualty Insurance (6331)

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 91359V107